Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases
S Yavuzyigitoglu, AE Koopmans, RM Verdijk… - Ophthalmology, 2016 - Elsevier
S Yavuzyigitoglu, AE Koopmans, RM Verdijk, J Vaarwater, B Eussen, A Van Bodegom…
Ophthalmology, 2016•ElsevierPurpose To investigate the prevalence and prognostic value of SF3B1 and EIF1AX
mutations in uveal melanoma (UM) patients. Design Case series. Participants Cohort of 151
patients diagnosed with and treated for UM. Methods SF3B1 and EIF1AX mutations in
primary tumors were investigated using whole-exome sequencing (n= 25) and Sanger
sequencing (n= 151). For the detection of BAP1 mutations, a previously reported cohort of
90 patients was extended using BAP1 sequencing or immunohistochemistry. Main Outcome …
mutations in uveal melanoma (UM) patients. Design Case series. Participants Cohort of 151
patients diagnosed with and treated for UM. Methods SF3B1 and EIF1AX mutations in
primary tumors were investigated using whole-exome sequencing (n= 25) and Sanger
sequencing (n= 151). For the detection of BAP1 mutations, a previously reported cohort of
90 patients was extended using BAP1 sequencing or immunohistochemistry. Main Outcome …
Purpose
To investigate the prevalence and prognostic value of SF3B1 and EIF1AX mutations in uveal melanoma (UM) patients.
Design
Case series.
Participants
Cohort of 151 patients diagnosed with and treated for UM.
Methods
SF3B1 and EIF1AX mutations in primary tumors were investigated using whole-exome sequencing (n = 25) and Sanger sequencing (n = 151). For the detection of BAP1 mutations, a previously reported cohort of 90 patients was extended using BAP1 sequencing or immunohistochemistry.
Main Outcome Measures
The status of SF3B1, EIF1AX, and BAP1 in tumors of patients were correlated to clinical, histopathologic, and genetic parameters. Survival analyses were performed for patients whose tumors had SF3B1, EIF1AX, and BAP1 mutations.
Results
Patients with tumors harboring EIF1AX mutations rarely demonstrated metastases (2 of 28 patients) and overall had a longer disease-free survival (DFS; 190.1 vs. 100.2 months; P < 0.001). Within the patient group with disomy 3, UM patients with an SF3B1 mutation had an increased metastatic risk compared with those without an SF3B1 mutation (DFS, 132.8 vs. 174.4 months; P = 0.008). Patients with such a mutation were more prone to demonstrate late metastases (median, 8.2 years; range, 23–145 months). Patients with UM and loss of BAP1 expression had a significantly decreased survival (DFS, 69.0 vs. 147.9 months; P < 0.001).
Conclusions
According to our data, patients with UM can be classified into 3 groups, of which EIF1AX-mutated tumors and tumors without BAP1, SF3B1, or EIF1AX mutations are associated with prolonged survival and low metastatic risk, SF3B1-mutated tumors are associated with late metastasis, and tumors with an aberrant BAP1 are associated with an early metastatic risk and rapid decline in patient DFS.
Elsevier